Sandoz Unveils Zero-Profit COVID-19 Portfolio
Dexamethasone On List For Low-Income Countries
Lutz Hegemann, chief operating officer for global health at Novartis, says the project will continue until a vaccine or curative treatments have reached the world's poorest places, not just until they are first approved in a high income country.
You may also be interested in...
Dexamethasone Shows Potential Of Repurposed Generics Against COVID-19
Positive trial results for dexamethasone in treating COVID-19 patients demonstrate the potential of repurposing existing generic medicines to fight the coronavirus pandemic.
Dexamethasone COVID-19 Findings Leave Authorities Bracing for Yet Another Demand Surge
Regulators whipsawed by COVID-19-related drug shortages are seeking better ways to forecast demand.
Coronavirus Notebook: Dexamethasone Reduces Deaths In Hospitalized COVID-19 Patients
The standout development in this latest Coronavirus Notebook is that the cheap and plentiful steroid dexamethasone has been shown to reduce deaths by a third in ventilated COVID-19 patients in the UK Recovery trial. In other news, there is fresh funding for smaller firms working on potential treatments and vaccines, and a number of organizations have decided to make their research tools and resources available free of charge in return for open publication of any coronavirus-related findings.